“It’s a version of an experiment. You have to really treat that, in my mind, as an experiment and get people’s informed consent.” — Arthur Caplan, PhD, of NYU Grossman School of Medicine, on changing COVID-19 vaccine dosing from what was tested in the registration trials.
“Hard to argue with results from 40,000 patients.” — Lauren Sorce, PhD, RN, of Northwestern University in Chicago, discussing a study showing lower mortality and shorter hospital stay for children with sepsis treated with bundled care.
“It’s really supply and demand here. We’ve got high demand and limited supply.” — Bonnie Litvack, MD, president of the Medical Society of the State of New York, on the shortage of COVID-19 vaccines for community doctors.
“The fact that you can actually assess the [ER] function in the body was amazing.” — Farrokh Dehdashti, MD, of Washington University in St. Louis, commenting on a study of PET imaging to predict response to endocrine therapy for breast cancer.
“There is a desperate need for improved healthcare and safety measures for people with chronic pain taking prescribed opioids so they are not subjected to unethical and dangerous practices.” — Beth Darnall, PhD, director of the Stanford University Pain Relief Innovations Lab, about Medicare patients who had their long-term opioid therapy stopped abruptly.
“The drug overdose crisis in the U.S. continues, and mortality involving psychoactive stimulant drugs is rising.” — Joshua Black, PhD, of Denver Health’s Rocky Mountain Poison and Drug Safety division in Colorado, about cocaine-, methamphetamine-, and amphetamine-involved death rates doubling every 4 years since 2010.